title: NUT midline carcinoma.
abstract: NUT midline carcinoma, a squamous cell carcinoma, is one of the most aggressive human cancers, and there is a desperate need for effective therapies for patients with this disease. Will the new bromodomain and extra terminal (BET) inhibitors prove to be one such treatment for this rare and enigmatic cancer?
authors: Department of Pathology, Brigham and Women's Hospital, harvard Medical School, 75 Francis Street, Boston, Massachusetts, 02115, USA. cfrench@partners.org
authors: Christopher
authors: C
authors: French
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D018797:Cell Cycle Proteins; D050939:Gene Fusion; D015321:Gene Rearrangement; D006801:Humans; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D015513:Oncogene Proteins; D014157:Transcription Factors; D000092468:Bromodomain Containing Proteins
chemical_list: D018797:Cell Cycle Proteins; D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D015513:Oncogene Proteins; D014157:Transcription Factors; C441289:BRD4 protein, human; D000092468:Bromodomain Containing Proteins; C000630260:NUTM1 protein, human